Voloridge Investment Management LLC purchased a new position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 36,922 shares of the biopharmaceutical company’s stock, valued at approximately $1,702,000. Voloridge Investment Management LLC owned approximately 0.06% of Agios Pharmaceuticals as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of AGIO. Quantamental Technologies LLC bought a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $28,000. Advisor Group Inc. grew its position in shares of Agios Pharmaceuticals by 33.1% in the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 297 shares during the period. ETF Managers Group LLC boosted its holdings in shares of Agios Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 216 shares during the period. MML Investors Services LLC bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $255,000. Finally, Pacer Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $257,000. 98.77% of the stock is owned by hedge funds and other institutional investors.
NASDAQ AGIO traded down $1.47 on Monday, hitting $59.85. 251,061 shares of the company were exchanged, compared to its average volume of 461,625. The firm has a market cap of $3.53 billion, a PE ratio of -9.93 and a beta of 2.38. Agios Pharmaceuticals Inc has a 12 month low of $41.63 and a 12 month high of $99.82.
Several brokerages recently commented on AGIO. BidaskClub downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. Svb Leerink upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Friday, February 15th. Finally, Piper Jaffray Companies lowered their price objective on shares of Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 14th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $97.86.
In other news, insider Scott Biller sold 9,000 shares of the stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $65.00, for a total value of $585,000.00. Following the completion of the sale, the insider now owns 28,277 shares in the company, valued at $1,838,005. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steven L. Hoerter sold 10,000 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $67.01, for a total transaction of $670,100.00. Following the completion of the sale, the insider now owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,000 shares of company stock valued at $2,765,530. 3.02% of the stock is currently owned by corporate insiders.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Recommended Story: Asset Allocation and Your Retirement
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.